STOCK TITAN

[8-K/A] Onto Innovation Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

The filing is a Form 144 notice covering a proposed insider sale of Doximity, Inc. (DOCS) common stock.

  • Seller: Regina M. Benjamin (relationship to issuer not specified).
  • Shares to be sold: 5,000 common shares.
  • Aggregate market value: US $300,200.
  • Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Approximate sale date: 11 July 2025 on the NYSE.
  • Shares outstanding: 187,826,153, making the proposed sale about 0.0027 % of outstanding shares.
  • Source of shares: Acquired via stock-option exercise on 11 July 2025; paid in cash.
  • Prior sales: The seller disposed of 10,000 shares on 25 June 2025 for gross proceeds of US $600,000.

No additional financial metrics, earnings figures, or strategic information are provided. The notice is routine and does not appear material to Doximity’s capital structure or operations.

La comunicazione riguarda un avviso Modulo 144 relativo a una proposta di vendita da parte di un insider di azioni ordinarie di Doximity, Inc. (DOCS).

  • Venditore: Regina M. Benjamin (rapporto con l'emittente non specificato).
  • Azioni da vendere: 5.000 azioni ordinarie.
  • Valore di mercato complessivo: 300.200 US$.
  • Intermediario: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8° piano, New York, NY 10004.
  • Data approssimativa della vendita: 11 luglio 2025 alla NYSE.
  • Azioni in circolazione: 187.826.153, rendendo la vendita proposta circa lo 0,0027 % delle azioni in circolazione.
  • Origine delle azioni: Acquisite tramite esercizio di opzioni azionarie l'11 luglio 2025; pagamento in contanti.
  • Vendite precedenti: Il venditore ha ceduto 10.000 azioni il 25 giugno 2025 per un ricavo lordo di 600.000 US$.

Non sono forniti ulteriori dati finanziari, risultati o informazioni strategiche. L’avviso è di routine e non sembra rilevante per la struttura del capitale o le operazioni di Doximity.

La presentación es un aviso de Formulario 144 que cubre una propuesta de venta por parte de un insider de acciones ordinarias de Doximity, Inc. (DOCS).

  • Vendedor: Regina M. Benjamin (relación con el emisor no especificada).
  • Acciones a vender: 5.000 acciones ordinarias.
  • Valor de mercado agregado: 300.200 US$.
  • Corredor: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8º piso, Nueva York, NY 10004.
  • Fecha aproximada de venta: 11 de julio de 2025 en la NYSE.
  • Acciones en circulación: 187.826.153, haciendo que la venta propuesta sea aproximadamente el 0,0027 % de las acciones en circulación.
  • Fuente de las acciones: Adquiridas mediante ejercicio de opciones sobre acciones el 11 de julio de 2025; pagadas en efectivo.
  • Ventas previas: El vendedor dispuso de 10.000 acciones el 25 de junio de 2025 por ingresos brutos de 600.000 US$.

No se proporcionan métricas financieras adicionales, cifras de ganancias ni información estratégica. El aviso es rutinario y no parece material para la estructura de capital o las operaciones de Doximity.

이 제출 서류는 Doximity, Inc. (DOCS)의 내부자 주식 매각 예정에 관한 Form 144 통지입니다.

  • 판매자: Regina M. Benjamin (발행인과의 관계 미명시).
  • 판매할 주식 수: 보통주 5,000주.
  • 총 시장 가치: 미화 300,200달러.
  • 중개인: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8층, 뉴욕, NY 10004.
  • 예상 매각일: 2025년 7월 11일, NYSE에서.
  • 발행 주식 수: 187,826,153주로, 제안된 매각은 전체 발행 주식의 약 0.0027%에 해당.
  • 주식 출처: 2025년 7월 11일 주식 옵션 행사로 취득; 현금 지불.
  • 이전 매각 내역: 판매자는 2025년 6월 25일에 10,000주를 매각하여 총 600,000달러를 확보.

추가 재무 지표, 수익 수치 또는 전략적 정보는 제공되지 않았습니다. 이 통지는 일상적이며 Doximity의 자본 구조나 운영에 중대한 영향을 미치지 않는 것으로 보입니다.

Le dépôt concerne un avis Formulaire 144 couvrant une vente proposée par un initié d’actions ordinaires de Doximity, Inc. (DOCS).

  • Vendeur : Regina M. Benjamin (relation avec l’émetteur non précisée).
  • Actions à vendre : 5 000 actions ordinaires.
  • Valeur marchande agrégée : 300 200 USD.
  • Intermédiaire : Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8e étage, New York, NY 10004.
  • Date approximative de vente : 11 juillet 2025 à la NYSE.
  • Actions en circulation : 187 826 153, la vente proposée représentant environ 0,0027 % des actions en circulation.
  • Source des actions : Acquises par exercice d’options sur actions le 11 juillet 2025 ; paiement en espèces.
  • Ventes antérieures : Le vendeur a cédé 10 000 actions le 25 juin 2025 pour un produit brut de 600 000 USD.

Aucune autre donnée financière, chiffre de résultats ou information stratégique n’est fournie. L’avis est de routine et ne semble pas significatif pour la structure du capital ou les opérations de Doximity.

Die Einreichung ist eine Formular 144-Meldung, die einen geplanten Insider-Verkauf von Stammaktien der Doximity, Inc. (DOCS) betrifft.

  • Verkäufer: Regina M. Benjamin (Beziehung zum Emittenten nicht angegeben).
  • Zu verkaufende Aktien: 5.000 Stammaktien.
  • Gesamtmarktwert: 300.200 US-Dollar.
  • Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8. Etage, New York, NY 10004.
  • Ungefähres Verkaufsdatum: 11. Juli 2025 an der NYSE.
  • Ausstehende Aktien: 187.826.153, was den geplanten Verkauf auf etwa 0,0027 % der ausstehenden Aktien ausmacht.
  • Herkunft der Aktien: Erwerb durch Ausübung von Aktienoptionen am 11. Juli 2025; bar bezahlt.
  • Vorherige Verkäufe: Der Verkäufer veräußerte am 25. Juni 2025 10.000 Aktien und erzielte einen Bruttoerlös von 600.000 US-Dollar.

Es werden keine weiteren finanziellen Kennzahlen, Gewinnzahlen oder strategischen Informationen bereitgestellt. Die Meldung ist routinemäßig und scheint für die Kapitalstruktur oder den Betrieb von Doximity nicht wesentlich zu sein.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 15,000 cumulative insider sales over 3 months equal 0.008 % of shares—immaterial, sentiment neutral.

The Form 144 discloses a modest planned sale of 5,000 DOCS shares (≈US$300k). Including the 10,000 shares already sold in June, the insider has sold 15,000 shares worth roughly US$0.9 million. Against 187.8 million outstanding shares, the combined volume is below 0.01 %, offering no meaningful dilution or price impact. The filing contains no operational or financial data; therefore, it does not alter the investment thesis. Insider transactions of this scale are typically viewed as personal liquidity events rather than signaling. Overall impact is neutral.

La comunicazione riguarda un avviso Modulo 144 relativo a una proposta di vendita da parte di un insider di azioni ordinarie di Doximity, Inc. (DOCS).

  • Venditore: Regina M. Benjamin (rapporto con l'emittente non specificato).
  • Azioni da vendere: 5.000 azioni ordinarie.
  • Valore di mercato complessivo: 300.200 US$.
  • Intermediario: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8° piano, New York, NY 10004.
  • Data approssimativa della vendita: 11 luglio 2025 alla NYSE.
  • Azioni in circolazione: 187.826.153, rendendo la vendita proposta circa lo 0,0027 % delle azioni in circolazione.
  • Origine delle azioni: Acquisite tramite esercizio di opzioni azionarie l'11 luglio 2025; pagamento in contanti.
  • Vendite precedenti: Il venditore ha ceduto 10.000 azioni il 25 giugno 2025 per un ricavo lordo di 600.000 US$.

Non sono forniti ulteriori dati finanziari, risultati o informazioni strategiche. L’avviso è di routine e non sembra rilevante per la struttura del capitale o le operazioni di Doximity.

La presentación es un aviso de Formulario 144 que cubre una propuesta de venta por parte de un insider de acciones ordinarias de Doximity, Inc. (DOCS).

  • Vendedor: Regina M. Benjamin (relación con el emisor no especificada).
  • Acciones a vender: 5.000 acciones ordinarias.
  • Valor de mercado agregado: 300.200 US$.
  • Corredor: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8º piso, Nueva York, NY 10004.
  • Fecha aproximada de venta: 11 de julio de 2025 en la NYSE.
  • Acciones en circulación: 187.826.153, haciendo que la venta propuesta sea aproximadamente el 0,0027 % de las acciones en circulación.
  • Fuente de las acciones: Adquiridas mediante ejercicio de opciones sobre acciones el 11 de julio de 2025; pagadas en efectivo.
  • Ventas previas: El vendedor dispuso de 10.000 acciones el 25 de junio de 2025 por ingresos brutos de 600.000 US$.

No se proporcionan métricas financieras adicionales, cifras de ganancias ni información estratégica. El aviso es rutinario y no parece material para la estructura de capital o las operaciones de Doximity.

이 제출 서류는 Doximity, Inc. (DOCS)의 내부자 주식 매각 예정에 관한 Form 144 통지입니다.

  • 판매자: Regina M. Benjamin (발행인과의 관계 미명시).
  • 판매할 주식 수: 보통주 5,000주.
  • 총 시장 가치: 미화 300,200달러.
  • 중개인: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8층, 뉴욕, NY 10004.
  • 예상 매각일: 2025년 7월 11일, NYSE에서.
  • 발행 주식 수: 187,826,153주로, 제안된 매각은 전체 발행 주식의 약 0.0027%에 해당.
  • 주식 출처: 2025년 7월 11일 주식 옵션 행사로 취득; 현금 지불.
  • 이전 매각 내역: 판매자는 2025년 6월 25일에 10,000주를 매각하여 총 600,000달러를 확보.

추가 재무 지표, 수익 수치 또는 전략적 정보는 제공되지 않았습니다. 이 통지는 일상적이며 Doximity의 자본 구조나 운영에 중대한 영향을 미치지 않는 것으로 보입니다.

Le dépôt concerne un avis Formulaire 144 couvrant une vente proposée par un initié d’actions ordinaires de Doximity, Inc. (DOCS).

  • Vendeur : Regina M. Benjamin (relation avec l’émetteur non précisée).
  • Actions à vendre : 5 000 actions ordinaires.
  • Valeur marchande agrégée : 300 200 USD.
  • Intermédiaire : Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8e étage, New York, NY 10004.
  • Date approximative de vente : 11 juillet 2025 à la NYSE.
  • Actions en circulation : 187 826 153, la vente proposée représentant environ 0,0027 % des actions en circulation.
  • Source des actions : Acquises par exercice d’options sur actions le 11 juillet 2025 ; paiement en espèces.
  • Ventes antérieures : Le vendeur a cédé 10 000 actions le 25 juin 2025 pour un produit brut de 600 000 USD.

Aucune autre donnée financière, chiffre de résultats ou information stratégique n’est fournie. L’avis est de routine et ne semble pas significatif pour la structure du capital ou les opérations de Doximity.

Die Einreichung ist eine Formular 144-Meldung, die einen geplanten Insider-Verkauf von Stammaktien der Doximity, Inc. (DOCS) betrifft.

  • Verkäufer: Regina M. Benjamin (Beziehung zum Emittenten nicht angegeben).
  • Zu verkaufende Aktien: 5.000 Stammaktien.
  • Gesamtmarktwert: 300.200 US-Dollar.
  • Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8. Etage, New York, NY 10004.
  • Ungefähres Verkaufsdatum: 11. Juli 2025 an der NYSE.
  • Ausstehende Aktien: 187.826.153, was den geplanten Verkauf auf etwa 0,0027 % der ausstehenden Aktien ausmacht.
  • Herkunft der Aktien: Erwerb durch Ausübung von Aktienoptionen am 11. Juli 2025; bar bezahlt.
  • Vorherige Verkäufe: Der Verkäufer veräußerte am 25. Juni 2025 10.000 Aktien und erzielte einen Bruttoerlös von 600.000 US-Dollar.

Es werden keine weiteren finanziellen Kennzahlen, Gewinnzahlen oder strategischen Informationen bereitgestellt. Die Meldung ist routinemäßig und scheint für die Kapitalstruktur oder den Betrieb von Doximity nicht wesentlich zu sein.

0000704532true00007045322025-06-122025-06-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2025

 

 

Onto Innovation Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39110

94-2276314

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

16 Jonspin Road

 

Wilmington, Massachusetts

 

01887

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (978) 253-6200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

ONTO

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Explanatory Note.

 

Onto Innovation, Inc. is filing an amendment to its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 12, 2025 (the “Original Form 8-K”) solely for the purpose of disclosing the material terms of the separation agreement with Mr. Mark Slicer, the Company’s former Chief Financial Officer, which was entered into as of July 9, 2025. Other than as set forth in this Explanatory Note, this amendment does not amend any other disclosures in the Original Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 12, 2025 (the “Separation Date”), Onto Innovation, Inc. (the “Company” or “Onto Innovation”) and Mr. Mark Slicer, the Company’s Chief Financial Officer (“CFO”), agreed to mutually terminate Mr. Slicer’s employment with the Company, effective immediately. Mr. Slicer served as the principal financial officer and principal accounting officer of the Company. The separation between the Company and Mr. Slicer was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

(e) On July 9, 2025, the Company and Mr. Slicer entered into a separation agreement (the “Separation Agreement”), effective as of July 16, 2025 (the “Effective Date”), in connection with Mr. Slicer’s separation from service with the Company.

Pursuant to the Separation Agreement, the Company, in exchange for Mr. Slicer’s general release and waiver of claims, has agreed, among other things:

(1)
to pay Mr. Slicer a separation fee in the amount equal to one (1) time his annual base salary, as in effect on the Separation Date ($477,405.00), in substantially equal installments for a period of twelve (12) months following the Effective Date in accordance with the Company’s standard payroll practices for senior executives;

(2)
to pay Mr. Slicer a pro rata incentive compensation payment for 2025 under the Company’s Annual Cash Incentive Plan, with a target cash payment of 70% of his annual base salary in effect on the Separation Date, based on actual business and personal performance, pro-rated based on the number of days during the 2025 calendar year that Mr. Slicer was employed by the Company prior to the Separation Date, payable in a lump sum in accordance with the Company’s executive bonus payment cycle and subject to appropriate income tax and other deductions;

(3)
to accelerate the vesting of any unvested restricted stock units granted to Mr. Slicer that would have vested during the twelve (12) month period following the Separation Date;

(4)
with respect to performance share units (“PSUs”) granted on or before the Separation Date that would have vested during the twelve (12) month period following the Separation Date, (A) to accelerate the vesting of any such PSUs vesting on a time basis and (B) that any such PSUs that are subject to performance conditions will remain outstanding and subject to such conditions and vest after the end of the performance period, but in no event later than March 15, 2026, at the value determined under the applicable performance plan;

(5)
that all other equity awards granted prior to the Separation Date but with a vesting date or performance measurement date subsequent to March 15, 2026 will be forfeited; and

(6)
to provide Mr. Slicer with a lump sum payment in gross amount of $39,190.65, which is equal to twelve (12) months of health and medical insurance premiums under the Consolidated Omnibus Budget Reconciliation Act of 1985.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.

Description of Exhibit

10.1*

Separation Agreement between Onto Innovation and Mark Slicer, dated July 9, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Certain identified information has been excluded from this exhibit in accordance with Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Onto Innovation Inc.

 

 

 

 

Date:

July 11, 2025

By:

/s/ Yoon Ah Oh

 

 

 

Yoon Ah Oh
Senior Vice President, General Counsel and Corporate Secretary

 


FAQ

How many Doximity (DOCS) shares are being sold under this Form 144?

The filing covers 5,000 common shares slated for sale.

What is the market value of the shares in this Form 144 filing?

The aggregate market value is US $300,200 based on the data provided.

When is the anticipated sale date for the Form 144 shares?

The seller plans to execute the trade on July 11, 2025 on the NYSE.

What percentage of Doximity’s outstanding shares does this sale represent?

The proposed 5,000-share sale equals approximately 0.0027 % of the 187,826,153 shares outstanding.

Were there prior insider sales by the same person within the last three months?

Yes. The insider sold 10,000 shares on June 25, 2025 for US $600,000.

Who is acting as broker for this planned transaction?

Morgan Stanley Smith Barney LLC is listed as the executing broker.

How were the shares to be sold acquired?

They were obtained via a stock-option exercise on July 11, 2025, paid in cash.
Onto Innovation Inc

NYSE:ONTO

ONTO Rankings

ONTO Latest News

ONTO Latest SEC Filings

ONTO Stock Data

5.09B
48.52M
0.65%
97.55%
3.06%
Semiconductor Equipment & Materials
Measuring & Controlling Devices, Nec
Link
United States
WILMINGTON